146 related articles for article (PubMed ID: 37271979)
21. Development and validation of a nomogram for predicting cefoperazone/sulbactam-induced hypoprothrombinaemia in Hospitalized adult patients.
Bai H; Li H; Nie X; Yao Y; Han X; Wang J; Peng L
PLoS One; 2023; 18(9):e0291658. PubMed ID: 37733780
[TBL] [Abstract][Full Text] [Related]
22. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients.
Winston DJ; Bartoni K; Bruckner DA; Schiller GJ; Territo MC
Clin Infect Dis; 1998 Mar; 26(3):576-83. PubMed ID: 9524826
[TBL] [Abstract][Full Text] [Related]
23. Serum trough concentration threshold and risk factors of cefoperazone-induced coagulopathy in critically ill patients: A retrospective case-control study.
Wang Q; Liang P; Xu Y; Yuan B; Lan C; Yan X; Li L
Eur J Clin Pharmacol; 2024 May; 80(5):737-746. PubMed ID: 38353692
[TBL] [Abstract][Full Text] [Related]
24. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
Ponraj M; Dubashi B; Harish BH; Kayal S; Cyriac SL; Pattnaik J; Ranjith K; Pillai US; Jadhav N; Matta KK; Singh J; Jaffa E; Prakash B
Support Care Cancer; 2018 Nov; 26(11):3899-3908. PubMed ID: 29774477
[TBL] [Abstract][Full Text] [Related]
25. Clinical Efficacy and Safety of Cefoperazone-Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and Meta-Analysis.
Lan SH; Chao CM; Chang SP; Lu LC; Lai CC
Surg Infect (Larchmt); 2021 Oct; 22(8):763-770. PubMed ID: 33625294
[No Abstract] [Full Text] [Related]
26. [Analysis of drug resistance of Pseudomonas aeruginosa and use of antibiotics in burn wards during 6 years].
Dou Y; Zhang Q
Zhonghua Shao Shang Za Zhi; 2014 Feb; 30(1):9-14. PubMed ID: 24684983
[TBL] [Abstract][Full Text] [Related]
27. Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam.
Qu YJ; Jin SB; Han XC; Zheng LQ
An Bras Dermatol; 2016; 91(6):808-810. PubMed ID: 28099605
[TBL] [Abstract][Full Text] [Related]
28. Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone. Report of three cases.
Alitalo R; Ruutu M; Valtonen V; Lehtonen T; Pentikäinen PJ
Ann Clin Res; 1985; 17(3):116-9. PubMed ID: 4051444
[TBL] [Abstract][Full Text] [Related]
29. Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra-abdominal infections.
Greenberg RN; Cayavec P; Danko LS; Bowen K; Montazemi R; Kearney PA; Johnson SB; Strodel WE
J Antimicrob Chemother; 1994 Sep; 34(3):391-401. PubMed ID: 7829413
[TBL] [Abstract][Full Text] [Related]
30. [Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders].
Ohno R; Hotta T; Ogura M; Ohnishi K; Morishita T; Murate T; Okumura M; Tanimoto M; Inoue C; Hamaguchi M
Jpn J Antibiot; 1989 Aug; 42(8):1713-9. PubMed ID: 2810734
[TBL] [Abstract][Full Text] [Related]
31. Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature.
Cai Z; Yang W; He Y; Chen Q; Wang S; Luo X; Wang X
Drug Saf Case Rep; 2016 Dec; 3(1):2. PubMed ID: 27747682
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
Gao C; Tong J; Yu K; Sun Z; An R; Du Z
Eur J Clin Pharmacol; 2016 Jul; 72(7):823-30. PubMed ID: 27023465
[TBL] [Abstract][Full Text] [Related]
33. Evaluation and survey of intravenous vitamin K1 for treatment of coagulopathy in critically ill patients.
MacLaren R; Wilson SJ; Campbell A; Anderson D; Rocker G
Pharmacotherapy; 2001 Feb; 21(2):175-82. PubMed ID: 11213854
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Safety of Generic Formulation of Cefoperazone/Sulbactam (Bacticep®) in Treatment of Infections at Siriraj Hospital.
Koomanachai P; Tongsai S; Thamlikitkul V
J Med Assoc Thai; 2016 Jan; 99(1):8-14. PubMed ID: 27455819
[TBL] [Abstract][Full Text] [Related]
35. Bloodstream infections caused by ST2 Acinetobacter baumannii: risk factors, antibiotic regimens, and virulence over 6 years period in China.
Yu K; Zeng W; Xu Y; Liao W; Xu W; Zhou T; Cao J; Chen L
Antimicrob Resist Infect Control; 2021 Jan; 10(1):16. PubMed ID: 33461617
[TBL] [Abstract][Full Text] [Related]
36. A case report of rash induced by cefoperazone sodium and sulbactam sodium plus metronidazole sodium chloride combined with morphine hydrochloride.
Huang J; Zhu X; Jiang C; Liu Z
Ann Palliat Med; 2020 Nov; 9(6):4377-4383. PubMed ID: 33302688
[TBL] [Abstract][Full Text] [Related]
37. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem.
Levin AS
Clin Microbiol Infect; 2002 Mar; 8(3):144-53. PubMed ID: 12010169
[TBL] [Abstract][Full Text] [Related]
38. A case of immune hemolytic anemia induced by ceftizoxime and cefobactam (sulbactam/cefoperazone).
Baek EJ; Lee S; Kim S; Choi HK; Kim HO
Korean J Lab Med; 2009 Dec; 29(6):578-84. PubMed ID: 20046091
[TBL] [Abstract][Full Text] [Related]
39. Use of cefoperazone/sulbactam in neonates.
Ovali F; Gursoy T; Sari I; Divrikli D; Aktas A
Pediatr Int; 2012 Feb; 54(1):60-3. PubMed ID: 21883691
[TBL] [Abstract][Full Text] [Related]
40. [Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis].
Suzuki K; Horiba M
Hinyokika Kiyo; 1991 Oct; 37(10):1333-43. PubMed ID: 1755429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
